ArticleFrontiers in endocrinology2026
Development and external validation of an admission-based model for 180-day mortality in diabetic acute myocardial infarction.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with diabetes mellitus and acute myocardial infarction (DM-AMI) are at high risk, but risk heterogeneity within this subgroup remains insufficiently characterized. Whether a parsimonious admission-based model provides prognostic information beyond GRACE remains uncertain. We aimed to assess admission risk heterogeneity in DM-AMI and develop and externally validate a model for 180-day mortality using routine variables. Methods: This retrospective dual-cohort study included AMI patients from a Beijing tertiary hospital (development cohort) and an ICU-based MIMIC-IV cohort (external validation). A Cox model was built using admission variables. Model performance was evaluated using discrimination, calibration, and decision curve analysis with internal bootstrap validation and comparison with GRACE. Results: Among 4,167 patients, 1,514 had DM-AMI with 90 deaths at 180 days. The model included eight variables (age, heart rate, SBP, glucose, BUN, hemoglobin, RDW, WBC). It showed good discrimination in the development cohort (C-index 0.848; AUC 0.857) and maintained performance externally (AUC 0.744). GRACE comparison showed similar discrimination, while the combined model improved performance (ΔAUC = 0.014, P = 0.031). Calibration in MIMIC-IV indicated risk overestimation (slope 0.527; O/E 0.652). Conclusion: DM-AMI patients exhibit marked admission risk heterogeneity. The model provides complementary prognostic information beyond GRACE but requires recalibration for absolute risk use in external settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.